CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 29 enrolled
Drug / intervention
LY3031207 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01449630
NCT01449630Phase 1Completed
CompareCT.gov

A Single-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of LY3031207 in Healthy Subjects

Eli Lilly and Company·interventional·Posted Oct 10, 2011·Updated Jul 5, 2019

In Brief

A Phase 1 clinical trial evaluating LY3031207, Placebo, and 1 other intervention for Healthy Volunteers. Completed, enrolled 29 participants across 1 site.

Detailed Summary

This is a phase I study of LY3031207 in healthy subjects. The purposes of this study are to look at safety, how well the study drug is tolerated, and how much of the study drug gets into the blood stream and how long it takes the body to get rid of it when given to humans. Information about any side effects that may occur will also be collected. Subjects will participate in the study for approximately 3 months. This study is for research purposes only and is not intended to treat any medical condition.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteers
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedOct 10, 2011
Enrollment StartOct 24, 2011
Primary CompletionApr 2, 2012
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 14.7 years ago

Interventions

LY3031207drug

Administered orally

Placebodrug

Administered orally

Celecoxibdrug

Administered orally